Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,76 USD | -1,31% | -14,74% | -57,22% |
Omzet 2024 * | 283 mln. 265 mln. | Omzet 2025 * | 382 mln. 357 mln. | Marktkapitalisatie | 392 mln. 367 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -186 mln. -174 mln. | Nettowinst (verlies) 2025 * | -101 mln. -94,54 mln. | EV/omzet 2024 * | 2,48 x |
Nettoschuld 2024 * | 309 mln. 289 mln. | Nettoschuld 2025 * | 230 mln. 215 mln. | EV/omzet 2025 * | 1,63 x |
K/w-verhouding 2024 * |
-1,82
x | K/w-verhouding 2025 * |
-3,56
x | Werknemers | 597 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,52% |
Recentste transcriptie over Revance Therapeutics, Inc.
1 dag | -1,31% | ||
1 week | -14,74% | ||
Lopende maand | -23,58% | ||
1 maand | -29,12% | ||
3 maanden | -37,95% | ||
6 maanden | -59,44% | ||
Lopend jaar | -57,22% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 05-09-17 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 05-11-18 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 01-03-11 |
Mark Foley
CEO | Chief Executive Officer | 58 | 05-09-17 |
Jill Beraud
BRD | Director/Board Member | 63 | 04-06-19 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.18% | 0 M€ | 0,00% | - | |
0.14% | 0 M€ | 0,00% | - | |
0.06% | 509 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
17-04-24 | 3,76 | -1,31% | 1 740 205 |
16-04-24 | 3,81 | -4,03% | 2 419 418 |
15-04-24 | 3,97 | -3,87% | 2 122 130 |
12-04-24 | 4,13 | -6,98% | 1 578 349 |
11-04-24 | 4,44 | +0,68% | 1 882 132 |
uitgestelde koers Nasdaq, 17 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-57,22% | 392 mln. | |
-5,32% | 84,57 mld. | |
+2,11% | 39,93 mld. | |
-25,74% | 27,93 mld. | |
+52,98% | 24,21 mld. | |
-6,17% | 17,17 mld. | |
-31,09% | 13,93 mld. | |
-6,58% | 12,3 mld. | |
-16,04% | 11,84 mld. | |
-3,97% | 7,91 mld. |